XML 68 R54.htm IDEA: XBRL DOCUMENT v3.20.2
Subsequent Events (Details Narrative) - USD ($)
Oct. 30, 2020
Jun. 30, 2020
Sep. 30, 2020
Jun. 25, 2020
Jun. 24, 2020
Dec. 31, 2019
Subsequent Event [Line Items]            
Common stock, shares authorized     150,000,000     150,000,000
Common Stock [Member] | Restated 2015 Equity Incentive Plan [Member]            
Subsequent Event [Line Items]            
Number of common shares available for issuance       27,250,000 7,250,000  
Increasing the maximum number of stock awards       1,000,000 500,000  
Common stock, shares authorized       750,000,000 150,000,000  
GMP Note [Member]            
Subsequent Event [Line Items]            
Secured debt   $ 2,000,000        
Convertible note term   1 year        
Debt instrument interest   2.00%        
Debt instrument description   In June 2020, Mateon secured $2 million in debt financing, evidenced by a one year convertible note (the "GMP Note") from GMP, to conduct a clinical trial evaluating OT-101 against COVID-19 bearing 2% annual interest, and is personally guaranteed by Dr. Vuong Trieu, the Chief Executive Officer of Mateon.        
GMP Note [Member] | Subsequent Event [Member]            
Subsequent Event [Line Items]            
Cash paid to clinical trial organization $ 500,000